TargeGen announces initiation of clinical trial of JAK2 inhibitor TG101348 in myeloproliferative disease patients

News | 01. 31. 2008


TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases.